Cargando…
P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
Autores principales: | Palandri, F., Bartoletti, D., Breccia, M., Auteri, G., Elli, E. M., Trawinska, M. M., Polverelli, N., Tiribelli, M., Benevolo, G., Iurlo, A., Tieghi, A., Heidel, F. H., Caocci, G., Beggiato, E., Binotto, G., Cavazzini, F., Miglino, M., Bosi, C., Crugnola, M., Bocchia, M., Martino, B., Pugliese, N., Romagnoli, A. D., Mazzoni, C., Scaffidi, L., Isidori, A., Cattaneo, D., Krampera, M., Pane, F., Cilloni, D., Semenzato, G., Lemoli, R. M., Cuneo, A., Abruzzese, E., Vianelli, N., Cavo, M., Bonifacio, M., Palumbo, G. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430731/ http://dx.doi.org/10.1097/01.HS9.0000846908.10695.dd |
Ejemplares similares
-
P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB
por: Palandri, F., et al.
Publicado: (2022) -
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2022) -
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023) -
P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
por: Palandri, Francesca, et al.
Publicado: (2023) -
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023)